ChongXiu Sun | Molecular Pathology | Best Researcher Award

Posted on by China Scientist

Dr. ChongXiu Sun| Molecular Pathology | Best Researcher Award

Chongxiu Sun is a distinguished professor at Nanjing Medical University, specializing in basic medical sciences with a focus on cardiovascular diseases. Fluent in both English and Chinese, Professor Sun has made significant contributions to the understanding of endothelial dysfunction and its molecular regulation in cardiovascular health.

Dr. ChongXiu Sun| Nanjing Medical University | China

Profile

SCOPUS ID

ORCID ID

 🎓EARLY ACADEMIC PURSUITS:

  • Chongxiu Sun began her academic journey at Nanjing University, where she earned her PhD in 2006. During her doctoral studies, she delved deeply into the complexities of molecular biology, setting the stage for her future research in cardiovascular medicine.

 🏥 Professional Milestones:

    • 2015–Present: Professor, Nanjing Medical University
    • 2008–2014: Research Assistant Professor, University of California
    • 2006–2008: Postdoctoral Researcher, Harvard Medical School

    Her tenure at prestigious institutions like Harvard and the University of California enriched her expertise and allowed her to collaborate with global experts in the field.

🧬 Research Contributions:

  • Professor Sun’s research primarily investigates the role and molecular regulation of endothelial dysfunction in cardiovascular diseases. Her groundbreaking studies have shed light on mechanisms that lead to vascular inflammation and oxidative stress, advancing the understanding of critical pathways involved in heart and vascular diseases.

🌍 IMPACT AND INFLUENCE

  • Chongxiu Sun’s research has been instrumental in:
    • Enhancing the understanding of cardiovascular disease mechanisms.
    • Offering insights into potential therapeutic interventions targeting endothelial dysfunction.
    • Building cross-disciplinary collaborations, bridging basic and clinical sciences.

📊 ACADEMIC CITATIONS

  • As a Jiangsu Distinguished Professor since 2015, Chongxiu Sun has authored numerous influential publications, with citations reflecting her contributions to the field. Her work has been recognized by peers worldwide, reinforcing her standing as a thought leader in cardiovascular research.

🌟 LEGACY AND FUTURE CONTRIBUTIONS

  • Chongxiu Sun’s legacy lies in her dedication to understanding endothelial dysfunction and its implications for cardiovascular health. Looking ahead, she is expected to:

    • Expand her research into precision medicine approaches.
    • Mentor the next generation of medical scientists.
    • Continue influencing global health outcomes through her innovative work.

Conclusion

  • Dr. Chongxiu Sun is a strong candidate for the Best Researcher Award. Her extensive research experience, impactful publications, and commitment to advancing cardiovascular medicine make her a deserving nominee. Including her specific publication record, citation metrics, and key achievements in cardiovascular research would further strengthen her candidacy and showcase her significant contributions to medical science.

📄Publications

  • Non-canonical NF-κB contributes to endothelial pyroptosis and atherogenesis dependent on IRF-1
    Authors: Fan, X., Li, Q., Wang, Y., … Passerini, A.G., Sun, C.
    Journal: Translational Research, 2023
  • mTOR contributes to endothelium-dependent vasorelaxation by promoting eNOS expression and preventing eNOS uncoupling
    Authors: Wang, Y., Li, Q., Zhang, Z., … Simon, S.I., Sun, C.X.
    Journal: Communications Biology, 2022
  • Targeting the KCa3.1 channel suppresses diabetes-associated atherosclerosis via the STAT3/CD36 axis
    Authors: Jiang, X.-X., Bian, W., Zhu, Y.-R., … Chen, S.-L., Zhang, D.-M.
    Journal: Diabetes Research and Clinical Practice, 2022
  • mTOR inhibition promotes pneumonitis through inducing endothelial contraction and hyperpermeability
    Authors: Chen, X., Hu, C., Fan, X., … Passerini, A.G., Sun, C.
    Journal: American Journal of Respiratory Cell and Molecular Biology, 2021
  • Pathogenesis and Molecular Immune Mechanism of Calcified Aortic Valve Disease
    Authors: Bian, W., Wang, Z., Sun, C., Zhang, D.-M.
    Journal: Frontiers in Cardiovascular Medicine, 2021

Zongzhi Liu | Bioinformatics | Best Researcher Award

Posted on by China Scientist

Assoc Prof Dr.Zongzhi Liu | Bioinformatics | Best Researcher Award

Successful Research Projects:
  • Dr. Liu has led significant projects, including the study of RUNX3 methylation’s impact on T cell function and immunotherapy response. His successful acquisition of funding for multiple National Natural Science Foundation projects reflects his ability to secure resources for impactful research.
Assoc Prof Dr. Zongzhi Liu , Changping Laboratory, China

Profile

Scopus

🏛️Early Academic Pursuits

  • Zongzhi Liu’s academic journey is deeply rooted in the exploration of human diseases and immunotherapy. His early academic work laid the foundation for his current focus on the mechanisms of neurodegenerative diseases and tumor immunotherapy. By leveraging next-generation sequencing and bioinformatics, he has significantly contributed to the understanding of disease pathways and therapeutic targets.

👨‍🔬  Professional Endeavors

  • Liu’s professional endeavors are characterized by his commitment to precision medicine and epigenetic research. His notable projects include the development of epigenetic biomarkers for early cancer diagnosis and targeted therapy. His work with Runx3 knockout mouse models has provided critical insights into the epigenetic regulation of PD-1 tumor treatment response and resistance.

🔬 SCADEN Algorithm and Neurodegenerative Diseases

  • Liu utilized the SCADEN algorithm to predict primary pathways involved in neuron degeneration, specifically focusing on Alzheimer’s Disease (AD), Parkinson’s Disease (PD), and Amyotrophic Lateral Sclerosis (ALS). His research integrates behavioral experiments in mice to explore these mechanisms further.

🧫 Multi-Omics Analysis for Tumor Immunotherapy

  • Through multi-omics analysis, Liu identified epigenetic targets for tumor immunotherapy. His establishment of a Runx3 knockout mouse model was pivotal in demonstrating that Runx3 epigenetic reprogramming is a key regulator of PD-1 tumor treatment response and resistance.

🌐 Research and Innovations

  • Liu’s innovations extend to several high-impact projects:

    • Molecular Mechanism of T Cell Function: Studied the regulation of T cell function related to RUNX3 methylation reprogramming, funded by the National Natural Science Foundation (2023-2025).
    • Emerging Infectious Diseases: Contributed to pathogen identification and early warning technology for infectious diseases, as part of a national task (2021-2024).
    • Combined Immunotherapy: Investigated the synergistic effects of combined immunotherapy, with significant clinical implications (2016-2022).
    • Maternal Age and Pregnancy Outcomes: Explored the impact of advanced maternal age on pregnancy outcomes and offspring health (2018-2022).
    • Liquid Biopsy Technology: Evaluated liquid biopsy technology for early cancer screening and diagnosis (2019-2021).

🏢 Consultancy/Industry Projects

  • National Natural Science Foundation Project: Molecular mechanism study on T cell function regulation (2023-2025).
  • National Task Project: Study on pathogen identification and early warning technology (2021-2024).
  • National Key R&D Program: Research on combined immunotherapy (2016-2022).
  • National Natural Science Foundation Key Project: Impact of advanced maternal age on pregnancy outcomes (2018-2022).
  • Ministry of Science and Technology Key R&D Program: Liquid biopsy technology for early cancer diagnosis (2019-2021).

🌍 Impact and Influence

  • Liu’s research has significantly impacted the fields of neurodegenerative diseases and tumor immunotherapy. His work on epigenetic reprogramming and precision medicine has paved the way for innovative approaches to early diagnosis and targeted therapy, influencing both clinical practices and future research directions.

👩‍🔬 Professional Memberships AND Collaborations

  • Zongzhi Liu holds esteemed editorial appointments as a reviewer for Frontiers in Oncology and Frontiers in Pediatrics, contributing his expertise to the peer-review process. His collaborative efforts span multiple prestigious institutions, including the General Hospital of the People’s Liberation Army of China, the Institute of Pathogen Biology at the Chinese Academy of Medical Sciences, Peking University Third Hospital, and the Cancer Hospital of the Chinese Academy of Medical Sciences. As a member of the Chinese Society for Cell Biology, Liu actively participates in advancing the field of bioinformatics in human diseases. His research focuses on bioinformatics, with a particular interest in the mechanisms of neurodegenerative diseases and tumor immunotherapy, underscoring his commitment to the intersection of epigenetics and precision medicine.

🌟 Legacy and Future Contributions

  • Liu’s legacy in the scientific community is marked by his groundbreaking research and dedication to advancing medical science. His future contributions are anticipated to further enhance our understanding of disease mechanisms and therapeutic strategies, ultimately improving patient outcomes and shaping the future of precision medicine.

📄Publications

  • Epigenetic reprogramming of Runx3 reinforces CD8 + T-cell function and improves the clinical response to immunotherapy
    • Authors: Liu, Z., Li, X., Gao, Y., Mei, Q., Sun, Y.
    • Journal: Molecular Cancer, 2023, 22(1), 84
  • CRISPR-Cas13d effectively targets SARS-CoV-2 variants, including Delta and Omicron, and inhibits viral infection
    • Authors: Liu, Z., Gao, X., Kan, C., Zhang, Z., Sun, Y.
    • Journal: MedComm, 2023, 4(1), e208
  • Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study
    • Authors: Jing, C., Wang, J., Zhu, M., Zhang, Z., Deng, W.
    • Journal: Cancer Immunology, Immunotherapy, 2022, 71(11), pp. 2597–2608
  • Whole-genome circulating tumor DNA methylation landscape reveals sensitive biomarkers of breast cancer
    • Authors: Hai, L., Li, L., Liu, Z., Tong, Z., Sun, Y.
    • Journal: MedComm, 2022, 3(3), e134
  • Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming
    • Authors: Wang, Y., Tong, C., Dai, H., Zhang, Y., Han, W.
    • Journal: Nature Communications, 2021, 12(1), 409